Target Price: ₹610
Current Market Price (CMP): ₹553.05
Indegene has announced its acquisition of BioPharm, a move designed to enhance its brand activation capabilities and boost its marketing campaign execution services. The total cost of the acquisition amounts to $104 million, which includes earnouts of $27 million. This values BioPharm at a multiple of 9.7 times its trailing EV/EBITDA for the calendar year 2024. BioPharm is noted for its robust EBITDA margin of 27% based on net revenue, and management anticipates the acquisition will be accretive to earnings per share (EPS) in approximately five to six quarters.
BioPharm specializes in working with brand owners, offering extensive expertise in omnichannel digital marketing, brand activation, and campaign execution. This acquisition will allow Indegene to deepen its engagement across various marketing channels including email, programmatic, video, display, social, and native technologies. Furthermore, BioPharm brings a data repository compiled over two decades, with 1.8 million and 3 million records, providing a comprehensive perspective on healthcare professional (HCP) engagement. The firm will also enhance Indegene’s reach into therapeutic areas such as oncology and rare diseases, as well as targeting niche HCP markets, including ophthalmology, backed by over 20 years of industry experience.
Following the acquisition, revenue estimates have been adjusted upwards by 5%, 10%, and 10% for fiscal years 2026, 2027, and 2028 respectively. However, EPS projections have been reduced by 0.5%, 2.8%, and 0.6% for the same years, attributed to anticipated margin declines due to transaction-related costs, integrations, and depreciation and amortization expenses, along with a decrease in other income. The valuation continues to be based on a target multiple of 26 times the expected EPS for the fiscal year ending September 2027, estimated at ₹23, resulting in a target price of ₹610. The recommendation stands at “Add.”
Published on October 7, 2025.
